At ECTRIMS 2025, experts discussed using AI-powered unstructured data processing to enhance understanding of drug efficacy, safety, and patient outcomes in multiple sclerosis. [WATCH TIME: 3 minutes]
John Foley, MD, FAAN
Advertisement
Articles by John Foley, MD, FAAN
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 2a INFORM-MS Trial to Study Anti-CD3 Agent Foralumab in Nonactive Secondary Progressive MS
2
Gene Therapy AMT-130 Meets End Points in Huntington Study, FDA Submission to Follow
3
Phase 3 Topline Results Show Rituximab Noninferior to Cladribine in Reducing New or Enlarging Brain Lesions in Relapsing-Remitting MS
4
Leveraging Artificial Intelligence to Extract Real-World Insights in Multiple Sclerosis: Rebekah Foster, MBA, and John Foley, MD, FAAN
5
